Specific-mutational patterns of p53 gene in bladder transitional cell carcinoma among a group of Iraqi patients exposed to war environmental hazards

Table 2 Association between p53 mutations as analyzed by SSCP and DNA sequencing, p53 immunoreactivty and p53 status with clinicopathological features

Variable	Patients No.	p53 mutation (5-8 exons) No. (%)				p53 nuclear reactivity No. (%)							p53 status No. (%)
Variable	Patients No.	p53 mut	p53 wt	OR	95%CI	Negative			Positive			P value	altered	Non- altered	P value
						-	+/-	Total	+	++	Total
Total	29	11(37.9)	18(62.1)			6(20.7)	6(20.7)	12(41.4)	3(10.3)	14(48.3)	17(58.6)		21(72.4)	8(27.6)
Grade
Low(I&II)	14	5(35.7)	9(64.3)	1.2	0.26-5.4	4(28.6)	5(35.7)	9(64.3)	1(7.1)	4(28.6)	5(35.7)	0.02	7(50)	7(50)	0.01
High (III)	15	6(40)	9(60)			2(13.3)	1(6.7)	3(20)	2(13.3)	10(66.7)	12(80)		14(93.3)	1(6.9)
Stage
Low(Ta&T1)	14	5(35.7)	9(64.3)	1.2	0.26-5.4	4(28.6)	5(35.7)	9(64.3)	1(7.1)	4(28.6)	5(35.7)	0.02	7(50)	7(50)	0.01
High (T2)	15	6(40)	9(60)			2(13.3)	1(6.7)	3(20)	2(13.3)	10(66.7)	12(80)		14(93.3)	1(6.9)

Negative indicates that less than 10% of tumor nuclei demonstrated p53 immunoreactivty, positive; 10% or more of tumor nuclei demonstrated p53 immunoreactivty, p53 status; + has alteration (mutation, or immunoreactivty score +,++, or both), - no alteration (mutation (−) and IHC (score -, +/−) for p53), OR, Odds Ratio; CI, Confidence Intervals, P Value ≤ 0.05 or 0.01 (Fisher’s exact probability test).

ISSN: 1756-0500